Glioblastoma; Paving the Way Toward Future Treatments PLUS A Conversation with Robert Patton

Glioblastoma; Paving the Way Toward Future Treatments PLUS A Conversation with Robert Patton Andrew Scarborough, BSc (Hons), PgCert - Isabella Cooper- FnDNutr., BSc (Hons), AFHEA, AMRSB, AfENDO
Glioblastoma (GBM) is the most common and aggressive malignant brain tumour in adults. The standard of care at diagnosis includes surgical resection, radiation, and chemotherapy. Little progress has been made to improve outcomes, with a median survival of 12 months from diagnosis.

One emerging strategy that differs from conventional GBM therapies is metabolic pathway targeting. At present there has yet to be any research outlining a metabolic phenotype of disease via observation of key biomarkers. To pave the way for future studies, it is key to establish what metabolic dysregulation looks like in a cohort of GBM patients to direct interventions. PLUS Necessity is the mother of invention they say. And sometimes the most obvious things are the path to the greatest changes.